Efficacy of short term valganciclovir in a standard-dose for cytomegalovirus prophylaxis in living donor kidney transplantation: a single-center report

DOI: https://doi.org/10.31450/ukrjnd.3(63).2019.03
Keywords: donor kidney transplantation, CMV infections,valganciclovir, prophylaxis.

Abstract

 Immunosuppressive drugs predispose the kidney transplant recipient to reactivation of сytomegalovirus (CMV) infections. Prophylaxis given to these patients is very important for the prevention of opportunistic CMV infections.

The objective of this study was to evaluate the short term and standard-dose valganciclovir prophylaxis for CMV infections in living donor kidney transplantation.

Methods. This study is retrospective one. Between April 2014 and April 2019 100 patients after living donor kidney transplantation with results CMV PCR-DNA and prophylactic treatment were studied retrospectively at Medipol University Medical Faculty Hospital Organ Transplantation Department, Istanbul, Turkey.

Results.The mean age was 38.3±15.6 years. 68 (68%) patients were males and 32 (32%) patients were females. All patients were treated with 900 mg daily and 90 days valganciclovir prophylaxis. Mean follow-up was 29.1±15 months. There were not detected CMV infections during the follow-up period.

Conclusions: Short term and standard-dosevalganciclovir prophylaxis appears to be successful prevention CMV infections in living donor kidney transplantation.

Downloads

Download data is not yet available.

References

1.Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006;20:401-409. doı: 10.1111/j.1399-0012.2006.00519.x


2.Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-1977.doi: 10.1056/NEJMoa060068


3. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10(3):60-5.


4. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20:202-13.doı: 10.1002/rmv.655


5. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B. et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of Cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20.doı: 10.1111/j.1600-6143.2004.00382.x


6. Kaden J, May G, Strobelt V, Groth J, Muller P. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve longterm results after kidney transplantation. Transplant Proc 1997;29:344-7.doı: 10.1016/s0041-1345(96)00301-6.


7. Nada R, Sachdeva MU, Sud K, Jha V, Joshi K. Co-infection by Cytomegalovirus and BK polyoma virus in renal allograft, mimicking acute rejection. Nephrol Dial Transplant. 2005; 20:994-6.doı: 10.1093/ndt/gfh737


8. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013;13:93-106.doı: 10.1111/ajt.12103


9. Morgantetti GF, Balancin ML, Guilherme AM, Márcio D, Silva GEB.Cytomegalovirus infection in kidney allografts: a review of literature.Transl Androl Urol2019;8:192-7.doi: 10.21037/tau.2018.10.14.


10. Jha V. Post-transplant infections: an ounce of prevention. Indian J Nephrol.2010; 20:171-8.doi: 10.4103/0971-4065.73431


11.Ljungman P, Griffiths P, Paya C. Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients. Clin Infect Dis 2002;34:1094-7. doi: 10.1086/339329


12. Sagedal S, Nordal KP, Hartmann A, Degré M, Holter E, Foss A et al. A Prospective Study of the Natural Course of Cytomegalovirus Infection and Disease in Renal Allograft Recipients. Transplantation 2000;70:1166-74. doı: 10.1097/00007890-200010270-00007.


13. Stratta RJ, Pietrangeli C, Baillie GM. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation. Pharmacotherapy 2010; 30:144-57.doı: 10.1592/phco.30.2.144.


14. Richardson WP, Colvin RB, Cheeseman SH, Tolkoff-Rubin NE, Herrin JT, Cosimi AB. et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med.1981; 305:57-63. doı: 10.1056/NEJM198107093050201


15. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: A clinician’s update. Am J Kidney Dis 2011;58:118-26.doi: 10.1053/j.ajkd.2011.04.010


16. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A. et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013;85:893-8. doi: 10.1002/jmv.23539.


17. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14:633-41.doi: 10.1007/s11908-012-0292-2.


18. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008;8:975-83.doi: 10.1111/j.1600-6143.2007.02133.x


19. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360. doi: 10.1097/TP.0b013e31829df29d.


20. Pinkerton H. The morphology of viral inclusions and their practical importance in the diagnosis of human disease. Am J Clin Pathol 1950;20:201-7.doi: 10.1093/ajcp/20.3.201.


21. Razonable RR, Humar A. AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transpl 2013; 13:93-106.doi: 10.1111/ajt.12103.


22.Halim MA, Gheith OA, MakkeyaY, Nagib AM, Atta AF, Emam M. et al. Extended Efficacy of Low-Dose Valganciclovir forPrevention of Cytomegalovirus Disease in Intermediate-RiskKidney Transplant Recipients: Two-Year Follow-Up. Experimental and Clinical Transplantation 2019;3:339-43.doi: 10.6002/ect.2018.0020.


23. Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt- Potter L, Mohammed A, et al. Evaluation of low- versus highdose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Transplantation 2015;99: 1499-1505. doi: 10.1097/TP.0000000000000570.


24.Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J. Increased risk of breakthrough infections among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis 2015;17:163-73. doi: 10.1111/tid.12349.


25. Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, et al. Extended low dose valganciclovir is effective prophylaxis against Cytomegalovirus in high-risk kidney transplant recipients with near-complete eradication of late-onset disease. Transplant Proc 2016;48:2056-64. doi: 10.1016/j.transproceed.2016.05.004.


26. Brum S, Nolasco F, Sousa J, Ferreira A, Possante M, Pinto JR, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc 2008;40:752-54.doi: 10.1016/j.transproceed.2008.02.048.


27. Cordero E, Casasola C, Ecarma R, Danguilan R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant. Proc.2012;44: 694-700.doi: 10.1016/j.transproceed.2011.11.053.


Abstract views: 361
PDF Downloads: 17763
Published
2019-09-04
How to Cite
Ertugrul, G., & Yanaral, T. (2019). Efficacy of short term valganciclovir in a standard-dose for cytomegalovirus prophylaxis in living donor kidney transplantation: a single-center report. Ukrainian Journal of Nephrology and Dialysis, (3(63), 22-26. https://doi.org/10.31450/ukrjnd.3(63).2019.03
Issue
No 3(63) (2019): Ukrainian Journal of Nephrology and Dialysis
Section
Articles